Tadd Seaton Wessel

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Health Outlook Corp. is a health prediction company that uses modern proteomics to better predict health events and improve health outcomes. The company is based in New York, NY. The company's proprietary algorithms use statistical models of mortality risk that incorporate traditional factors and modern proteomic markers. Health Outlook is launching businesses that leverage its algorithms in the financial services and health systems markets. Health Outlook was founded by Tim Opler, and the CEO is Howard W. Sams.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Health Outlook Corp. is a health prediction company that uses modern proteomics to better predict health events and improve health outcomes. The company is based in New York, NY. The company's proprietary algorithms use statistical models of mortality risk that incorporate traditional factors and modern proteomic markers. Health Outlook is launching businesses that leverage its algorithms in the financial services and health systems markets. Health Outlook was founded by Tim Opler, and the CEO is Howard W. Sams.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Persivia, Inc. provides a clinical decision support and reporting analytics platform. It aggregates, analyzes and reports clinical data sets in the healthcare industry. The firm offers patient-centric clinical decision support, population health management, intelligent order sets, disease surveillance and regulatory reporting services. The company was founded by Mansoor Khan and is headquartered in Lowell, MA.

Persivia, Inc. provides a clinical decision support and reporting analytics platform. It aggregates, analyzes and reports clinical data sets in the healthcare industry. The firm offers patient-centric clinical decision support, population health management, intelligent order sets, disease surveillance and regulatory reporting services. The company was founded by Mansoor Khan and is headquartered in Lowell, MA.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

Health Outlook Corp. is a health prediction company that uses modern proteomics to better predict health events and improve health outcomes. The company is based in New York, NY. The company's proprietary algorithms use statistical models of mortality risk that incorporate traditional factors and modern proteomic markers. Health Outlook is launching businesses that leverage its algorithms in the financial services and health systems markets. Health Outlook was founded by Tim Opler, and the CEO is Howard W. Sams.

Health Outlook Corp. is a health prediction company that uses modern proteomics to better predict health events and improve health outcomes. The company is based in New York, NY. The company's proprietary algorithms use statistical models of mortality risk that incorporate traditional factors and modern proteomic markers. Health Outlook is launching businesses that leverage its algorithms in the financial services and health systems markets. Health Outlook was founded by Tim Opler, and the CEO is Howard W. Sams.